Psychiatry Research 1983-12-01

Short-lived effect of (Des-Tyr)-gamma-endorphin in schizophrenia.

J Volavka, K S Hui, B Anderson, Z Nemes, J O'Donnell, A Lajtha

Index: Psychiatry Res. 10(4) , 243-52, (1983)

Full Text: HTML

Abstract

Des-tyrosine-gamma-endorphin (DT gamma E) has been reported to alleviate symptoms of schizophrenia. Attempting to replicate those reports, we administered 1 mg of DT gamma E, i.m., for 8 consecutive days to nine patients meeting the DSM-III criteria for schizophrenia. Patients in this double-blind, crossover, and placebo-controlled study showed a statistically significant, but clinically modest improvement. The improvement was detectable during the first several days of the DT gamma E treatment; the symptoms then returned to baseline level in spite of continued doses of DT gamma E. Testing the metabolism of DT gamma E in the patients' plasma, we found a high rate of formation and of degradation, but the metabolic rates were not related to clinical symptoms.

Related Compounds

  • [Des-Tyr1] g-Endo...

Related Articles:

Interaction between des-Tyr1-gamma-endorphin and HLA class I molecules: serological detection of an HLA-A2 subtype.

1985-01-01

[Immunogenetics 22(4) , 309-14, (1985)]

Des-tyrosine-gamma-endorphin effects on morphine analgesia in mice.

1993-01-01

[Gen. Pharmacol. 24(1) , 83-8, (1993)]

Subchronic treatment with fragments of beta-endorphin prevents electroencephalographic seizures and behavioral alterations induced by centrally administered beta-endorphin in the rabbit.

1994-02-01

[J. Pharmacol. Exp. Ther. 268(2) , 1040-50, (1994)]

Criteria for evaluating improvement in schizophrenia in psychopharmacological research (with special reference to gamma endorphin fragments).

1988-09-01

[Br. J. Psychiatry 153 , 354-8, (1988)]

A treatment trial with an analog of thyrotropin-releasing hormone (DN-1417) and des-tyrosine-gamma-endorphin in schizophrenia.

1986-10-01

[Int. Clin. Psychopharmacol. 1(4) , 303-13, (1986)]

More Articles...